» Articles » PMID: 24211598

Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2013 Nov 12
PMID 24211598
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Urinary biomarker tests for diagnosing prostate cancer have gained considerable interest. Urine is a complex mixture that can be subfractionated. We evaluated 2 urinary fractions that contain nucleic acids, ie cell pellets and exosomes. The influence of digital rectal examination before urine collection was also studied and the prostate cancer specific biomarkers PCA3 and TMPRSS2-ERG were assayed.

Materials And Methods: Urine samples were prospectively obtained before and after digital rectal examination from 30 men scheduled for prostate biopsy. Cell pellet and exosomes were isolated and used for biomarker analysis. Analytical and diagnostic performance was tested using the Student t-test and ROC curves.

Results: Unlike the exosome fraction, urinary sediment gene expression analysis was compromised by amorphous precipitation in 10% of all specimens. Digital rectal examination resulted in increased mRNA levels in each fraction. This was particularly relevant for the exosomal fraction since after digital rectal examination the number of samples decreased in which cancer specific markers were below the analytical detection limit. Biomarker diagnostic performance was comparable to that in large clinical studies. In exosomes the biomarkers had to be normalized for prostate specific antigen mRNA while cell pellet absolute PCA3 levels had diagnostic value.

Conclusions: Exosomes have characteristics that enable them to serve as a stable substrate for biomarker analysis. Thus, digital rectal examination enhances the analytical performance of biomarker analysis in exosomes and cell pellets. The diagnostic performance of biomarkers in exosomes differs from that of cell pellets. Clinical usefulness must be prospectively assessed in larger clinical cohorts.

Citing Articles

Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response.

Hamid Y, Rabbani R, Afsara R, Nowrin S, Ghose A, Papadopoulos V Int J Mol Sci. 2025; 26(2).

PMID: 39859516 PMC: 11765602. DOI: 10.3390/ijms26020802.


Prostate cancer theragnostics biomarkers: An update.

Kumar Am S, Rajan P, Alkhamees M, Holley M, Lakshmanan V Investig Clin Urol. 2024; 65(6):527-539.

PMID: 39505512 PMC: 11543649. DOI: 10.4111/icu.20240229.


Unveiling potential: urinary exosomal mRNAs as non-invasive biomarkers for early prostate cancer diagnosis.

Yu J, Yu C, Jiang K, Yang G, Yang S, Tan S BMC Urol. 2024; 24(1):163.

PMID: 39090720 PMC: 11292860. DOI: 10.1186/s12894-024-01540-6.


Transcript Markers from Urinary Extracellular Vesicles for Predicting Risk Reclassification of Prostate Cancer Patients on Active Surveillance.

Erdmann K, Distler F, Grafe S, Kwe J, Erb H, Fuessel S Cancers (Basel). 2024; 16(13).

PMID: 39001515 PMC: 11240337. DOI: 10.3390/cancers16132453.


Cancer-associated fibroblast exosome LINC00355 promotes epithelial-mesenchymal transition and chemoresistance in colorectal cancer through the miR-34b-5p/CRKL axis.

Hu J, Tang H, Wang Y Cancer Gene Ther. 2023; 31(2):259-272.

PMID: 38052858 DOI: 10.1038/s41417-023-00700-4.